At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.
Krina Patel, MD, MSc
Advertisement
Articles by Krina Patel, MD, MSc
Updated iMMagine-1 data presented at ASH 2025 show that anito-cel delivers deep, durable responses in heavily pretreated multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure
2
Fuzuloparib Monotherapy Improves PFS in Advanced Ovarian Cancer, but Adding Apatinib Offers No Additional Benefit
3
Top 5 Inflammation Articles of 2025
4
FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
5
